Oral Proteins and Peptides

Global Oral Proteins and Peptides Market to Reach US$2.0 Billion by 2030

The global market for Oral Proteins and Peptides estimated at US$1.3 Billion in the year 2024, is expected to reach US$2.0 Billion by 2030, growing at a CAGR of 7.4% over the analysis period 2024-2030. Calcitonin Drug Type, one of the segments analyzed in the report, is expected to record a 6.1% CAGR and reach US$762.5 Million by the end of the analysis period. Growth in the Insulin Drug Type segment is estimated at 9.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$351.6 Million While China is Forecast to Grow at 11.3% CAGR

The Oral Proteins and Peptides market in the U.S. is estimated at US$351.6 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$411.9 Million by the year 2030 trailing a CAGR of 11.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.8% and 7.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.9% CAGR.

Global Oral Proteins and Peptides Market - Key Trends & Drivers Summarized

Why Has Oral Delivery of Proteins and Peptides Remained Technically Difficult?

Proteins and peptides are sensitive biological molecules with poor intrinsic stability in the digestive system. When administered orally, they face rapid degradation by gastric enzymes and harsh pH conditions, followed by limited intestinal absorption due to large molecular size and hydrophilicity. These barriers have historically limited oral use of therapeutic proteins, pushing most into parenteral routes. However, recent scientific progress is making oral delivery more plausible, driving new investment in peptide-based oral drug development.

The motivation behind oral delivery is strong, particularly for long-term treatments like diabetes, growth disorders, and hormonal deficiencies. Patients prefer oral therapies over injections for convenience, comfort, and reduced risk of injection-related complications. Hence, the pharmaceutical industry is actively working on approaches to stabilize peptide structures and promote mucosal transport for systemic absorption.

What Formulation Techniques Are Enabling Systemic Uptake via the GI Tract?

Several formulation strategies are under active development to enable oral delivery of peptides and proteins. Use of enteric-coated capsules and enzyme inhibitors helps protect the drug until it reaches the intestine. Absorption enhancers such as medium-chain fatty acids and bile salts are employed to loosen tight junctions in the intestinal lining, temporarily increasing permeability. Carrier systems like nanoparticles, self-emulsifying drug delivery systems (SEDDS), and lipid-based formulations are designed to improve drug solubility and stability.

Technologies such as permeation-enhancing microcontainers, mucoadhesive films, and transcellular transporters are being refined to achieve consistent and safe absorption. Structural modification of peptides, including cyclization and D-amino acid substitution, improves resistance to enzymatic cleavage without affecting biological activity. These methods are allowing more peptide drugs to achieve bioavailability levels sufficient for therapeutic effect.

Which Therapies Are Leading in Development and Where Is Innovation Concentrated?

Diabetes and metabolic disorders are the leading therapeutic segments for oral peptide development. Oral semaglutide, a GLP-1 receptor agonist for type 2 diabetes, is the most notable commercial success, marking a breakthrough in this space. Similar efforts are targeting oral formulations of insulin, parathyroid hormone, and calcitonin for osteoporosis and thyroid-related disorders.

Biopharmaceutical companies are also exploring oral delivery of peptide-based immunotherapies and anti-inflammatory agents for conditions such as rheumatoid arthritis and ulcerative colitis. North America and select European countries are leading innovation due to strong R&D infrastructure and regulatory engagement. Emerging economies are watching closely for cost-effective formulations to broaden access.

Growth in the Oral Proteins and Peptides market is driven by several factors…

Growth in the oral proteins and peptides market is driven by factors such as increasing demand for convenient alternatives to injectable biologics, progress in drug stabilization techniques, and growing therapeutic use of peptides in chronic diseases. Rising adoption of GLP-1 analogs and other metabolic treatments is fueling commercial interest in oral peptide delivery platforms.

Advancements in bioavailability enhancers, protective coatings, and intestinal absorption models are supporting wider application of peptide therapies in outpatient settings. Expansion of clinical pipelines, coupled with favorable patient preferences and emerging regulatory approvals, is creating a strong foundation for long-term market growth. Strategic partnerships between biotech firms and delivery technology companies are further accelerating the pace of innovation in this evolving field.

SCOPE OF STUDY:

The report analyzes the Oral Proteins and Peptides market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Drug Type (Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type, Plecanatide Drug Type); Application (Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application, Hormonal Disorders Application)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 32 Featured) -

• AbbVie Inc.
• Abbott Laboratories
• Amgen Inc.
• AstraZeneca PLC
• Biocon Limited
• Boehringer Ingelheim
• Bristol-Myers Squibb Company
• Chiasma Inc.
• Entera Bio Ltd.
• F. Hoffmann-La Roche Ltd.
• Eli Lilly and Company
• Merck & Co., Inc.
• Nektar Therapeutics
• Novo Nordisk A/S
• Oramed Pharmaceuticals Inc.
• Pfizer Inc.
• Protagonist Therapeutics, Inc.
• Proxima Concepts Limited
• Rani Therapeutics, LLC
• Sanofi S.A.
• Synergy Pharmaceuticals Inc.

AI INTEGRATIONS
We`re transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.